Post-earnings recap
Reported
Thu, Jul 28, 2011
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
BioMarin Pharmaceuticals reported a strong EPS performance, exceeding expectations significantly. However, the stock reacted negatively, declining by 0.88%. This could indicate investor concerns about the lack of revenue data and future guidance, which may affect confidence moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.12 | N/A | +203.45% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a sense of cautious optimism regarding the company's financial health. They noted the strong EPS performance as a positive sign.
Management expressed satisfaction with the EPS performance despite lacking revenue guidance.
They highlighted ongoing efforts to enhance product offerings and market presence.